Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Alkotinib

Alternative Names: alkotinib, zg-0418, zg0418, zg 0418
Latest Update: 2024-04-26
Latest Update Note: Clinical Trial Update

Product Description

Indicated for ALK/ROS1 mutant nonn-small cell lung cancer (Sourced from: https://www.zelgen.com/en/index.php/chanpinxian/)

Mechanisms of Action: ALK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Suzhou Zelgen
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer

Phase 1: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NSCLC

P1

Completed

Non-Small-Cell Lung Cancer

2022-10-17

34%
ZGALK002

P2

Terminated

Non-Small-Cell Lung Cancer

2022-10-11

31%
ZGALK003

P1

Completed

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2019-12-16

42%

Recent News Events

Date

Type

Title

08/10/2021

News Article

 Anaplastic Lymphoma Kinase ALK Inhibitors Market, 2026

07/06/2021

News Article

 2021 Anaplastic Lymphoma Kinase Inhibitors Pipeline Market Report - ResearchAndMarkets.com

07/01/2021

PubMed

 Substrate Channeling by a Rationally Designed Fusion Protein in a Biocatalytic Cascade.

04/22/2021

News Article

 Worldwide Anaplastic Lymphoma Kinase ALK Inhibitors Industry to 2026 - Featuring Astellas Pharma, AstraZeneca ad Pfizer Among Others

04/21/2021

News Article

 Insights on the Anaplastic Lymphoma Kinase ALK Inhibitors Global Market to 2026 - Lorbrena Overcomes Xalkori as Front-Line Therapy in NSCLC

04/17/2020

PubMed

 Retraction Note: Acute Toxicity and Gastroprotection Studies of a New Schiff Base Derived Manganese (II) Complex against HCl/Ethanol-Induced Gastric Ulcerations in Rats.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions